KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to $117.6 million.

  • Fulgent Genetics' Cash & Equivalents rose 10268.25% to $117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.6 million, marking a year-over-year increase of 10268.25%. This contributed to the annual value of $55.1 million for FY2024, which is 4342.64% down from last year.
  • As of Q3 2025, Fulgent Genetics' Cash & Equivalents stood at $117.6 million, which was up 10268.25% from $87.9 million recorded in Q2 2025.
  • Fulgent Genetics' Cash & Equivalents' 5-year high stood at $353.1 million during Q1 2022, with a 5-year trough of $54.7 million in Q1 2024.
  • For the 5-year period, Fulgent Genetics' Cash & Equivalents averaged around $114.9 million, with its median value being $87.9 million (2025).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 403249.69% in 2021, then tumbled by 8125.81% in 2023.
  • Fulgent Genetics' Cash & Equivalents (Quarter) stood at $164.9 million in 2021, then plummeted by 51.78% to $79.5 million in 2022, then grew by 22.6% to $97.5 million in 2023, then plummeted by 43.43% to $55.1 million in 2024, then skyrocketed by 113.33% to $117.6 million in 2025.
  • Its Cash & Equivalents stands at $117.6 million for Q3 2025, versus $87.9 million for Q2 2025 and $67.3 million for Q1 2025.